• We are a fully integrated vaccine company with two travel vaccines on the market.

  • Dedicated to innovation in vaccine research and development.

  • Valneva’s lead clinical late stage programs address hospital and healthcare associated infections.

  • Valneva covers the full value chain from research to market.

Welcome to Valneva
A leading pure play vaccine company.

2015 Annual Business Report

— August 31, 2016

Valneva Reports Strong Revenue Growth and Positive EBITDA in H1 Confirming the Company’s Trend towards EBITDA Break-even

Read more

— Stock information

@valnevase




















-
— July 25, 2016
Valneva Announces Successful Completion of Phase II for C. Diff Vaccine Candidate

Read more

— Financial Calendar



August 31, 2016
Valneva published its Q2/H1 2016 financial results Listen to the recording of the conference call here.

November 9, 2016
Q3 2016 Results

See all dates

JAPANESE
ENCEPHALITIS
AND
CHOLERA



learn more
play video Valneva's CEO Thomas Lingelbach
comments on Group Strategy

– Upcoming conferences and fairs



Jefferies London Healthcare Conference
London UK
November 16-17, 2016

Please update your browser...